Kyver­na Ther­a­peu­tics files for IPO as au­toim­mune CAR-T space heats up

Kyver­na Ther­a­peu­tics, a clin­i­cal-stage biotech ex­am­in­ing CAR-T cell ther­a­py’s po­ten­tial to treat au­toim­mune dis­eases, has filed for an ini­tial pub­lic of­fer­ing.

The Cal­i­for­nia biotech plans to list as “KYTX” on the Nas­daq, per SEC pa­per­work filed Tues­day. End­points News re­port­ed Fri­day that Kyver­na was con­sid­er­ing go­ing pub­lic as ear­ly as Feb­ru­ary.

Kyver­na joins an IPO queue of at least five oth­er biotechs look­ing to go pub­lic this year. That in­cludes late-stage can­cer drug­mak­ers CG On­col­o­gy and Ar­riVent Bio­phar­ma, Phase II biotech Al­to Neu­ro­science, pre­clin­i­cal gene edit­ing com­pa­ny Metageno­mi and obe­si­ty gene ther­a­py mak­er Fractyl Health, which have all filed for list­ings in re­cent weeks.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER